Our Services
Medical Information
Helpful Resources
Published on: 9/23/2026
Most RSV infections run 1 to 2 weeks from start to finish: symptoms usually begin 4 to 6 days after exposure, peak around days 3 to 5, and ease over the following week, though a dry cough can linger for 2 to 4 weeks. Contagiousness typically lasts 3 to 8 days, but infants and people with weakened immune systems can spread the virus for up to 4 weeks. Recovery timelines stretch longer for babies under 6 months, adults over 65, and anyone with asthma, COPD, or heart disease, and complications like bronchiolitis or pneumonia can change the picture entirely. There are several important factors and warning signs to consider, including when a "normal" RSV course has crossed into something that needs urgent care, so review the complete answer below before assuming you just need to wait it out.
Because RSV, flu, COVID-19, and a common cold can look nearly identical in the first few days, guessing wrong can mean missing the window when treatment and monitoring matter most, which is why it helps to run a free, instant, online symptom check to see how your specific symptoms, age, and health history line up and what step to take next.
Last reviewed for medical accuracy: 09/23/2026
Respiratory Syncytial Virus (RSV) is a common virus that infects the respiratory tract. It affects people of all ages but can be more serious in infants, older adults, and those with weakened immune systems. Understanding the timeline of RSV—from the first exposure to full recovery—can help you recognize what to expect and when to seek medical advice.
RSV progresses through several phases. While individual experiences vary, here’s a general framework:
Total duration, from first exposure to final symptom resolution, typically ranges from 7 to 21 days, though mild cough and tiredness can linger for a few weeks longer.
After you’re exposed to RSV—often via droplets from coughing or touching contaminated surfaces—you usually don’t feel sick right away. During the incubation period:
Because you can spread RSV before feeling ill, good hand hygiene and avoiding close contact with vulnerable people (like infants and older adults) are key preventive steps.
When symptoms begin, they often feel like a common cold:
In infants and older adults, RSV can lead to more severe lower respiratory tract issues such as bronchiolitis or pneumonia. Watch for:
Most healthy older children and adults start to feel noticeably better after about 5 to 7 days. However, symptom severity and duration depend on age, overall health, and whether complications arise.
After the worst of the symptoms pass, your body continues fighting residual inflammation and repairing damaged lung tissue. During this phase you may experience:
Most people see significant improvement by the end of the second week. If symptoms worsen, or if new symptoms like increased difficulty breathing develop, it’s important to get medical attention.
Even after feeling “back to normal,” some RSV effects can linger:
While this late-phase cough can be annoying, it typically doesn’t signal a new infection. If you experience high fever, chest pain, or worsening shortness of breath, contact your healthcare provider.
Most RSV cases are treated with supportive care. Here’s what you can do:
If you’re unsure about symptoms or need guidance on treatment options, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Most RSV infections resolve without hospital care. However, watch for these warning signs:
If any of these occur, seek prompt medical care or call emergency services.
RSV is highly contagious. To protect yourself and others:
Remember, a simple cough that drags on can feel discouraging, but it’s usually part of normal recovery. If you’re ever unsure about how RSV is affecting you or a loved one, don’t hesitate to seek professional help. And for quick guidance on your symptoms, try a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Always speak to a doctor about anything that could be life-threatening or seriously impact your health.
(References)
* Russell AB. Palivizumab: an overview. Hosp Med. 1999 Dec;60(12):873-7. doi: 10.12968/hosp.1999.60.12.1254. PMID: 10707171.
* Cingoz O. Motavizumab. MAbs. 2009 Sep-Oct;1(5):439-42. doi: 10.4161/mabs.1.5.9496. Epub 2009 Sep 10. PMID: 20065632; PMCID: PMC2759493.
* Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, Baker J, Pérez Marc G, Radley D, Shittu E, Glanternik J, Snaggs H, Baber J, Zachariah P, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Duron Padilla M, Richmond PC, Koury K, Schneider K, Kalinina EV, Cooper D, Jansen KU, Anderson AS, Swanson KA, Gruber WC, Gurtman A, MATISSE Study Group. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. PMID: 37018474.
* Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, Monroy J, Duncan CJA, Ujiie M, Rämet M, Pérez-Breva L, Falsey AR, Walsh EE, Dhar R, Wilson L, Du J, Ghaswalla P, Kapoor A, Lan L, Mehta S, Mithani R, Panozzo CA, Simorellis AK, Kuter BJ, Schödel F, Huang W, Reuter C, Slobod K, Stoszek SK, Shaw CA, Miller JM, Das R, Chen GL, ConquerRSV Study Group. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med. 2023 Dec 14;389(24):2233-2244. doi: 10.1056/NEJMoa2307079. PMID: 38091530.
* Dieussaert I, Hyung Kim J, Luik S, Seidl C, Pu W, Stegmann JU, Swamy GK, Webster P, Dormitzer PR. RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes. N Engl J Med. 2024 Mar 14;390(11):1009-1021. doi: 10.1056/NEJMoa2305478. PMID: 38477988.
* Sevendal ATK, Hurley S, Bartlett AW, Rawlinson W, Walker GJ. Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development. Rev Med Virol. 2024 Sep;34(5):e2576. doi: 10.1002/rmv.2576. PMID: 39209729.
* Munro APS, Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Vassilouthis NC, Carreno M, Moreau C, Bourron P, Marcelon L, Mari K, Roberts M, Tissières P, Royal S, Faust SN, HARMONIE Study Group. 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. Lancet Child Adolesc Health. 2025 Jun;9(6):404-412. doi: 10.1016/S2352-4642(25)00102-6. PMID: 40379431.
* Surie D, Self WH, Yuengling KA, Lauring AS, Zhu Y, Safdar B, Ginde AA, Simon SJ, Peltan ID, Brown SM, Gaglani M, Ghamande S, Columbus C, Mohr NM, Gibbs KW, Hager DN, Prekker M, Gong MN, Mohamed A, Johnson NJ, Steingrub JS, Khan A, Duggal A, Gordon AJ, Qadir N, Chang SY, Mallow C, Felzer JR, Kwon JH, Exline MC, Vaughn IA, Ramesh M, Papalambros L, Mosier JM, Harris ES, Baughman A, Cornelison SA, Blair PW, Johnson CA, Lewis NM, Ellington S, Grijalva CG, Talbot HK, Casey JD, Halasa N, Chappell JD, Rutkowski RE, Ma KC, Dawood FS, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA. 2025 Oct 28;334(16):1442-1451. doi: 10.1001/jama.2025.15896. PMID: 40884491; PMCID: PMC12398767.
* Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Skaarup KG, Modin D, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Jensen AMR, Dons M, Bernholm KF, Davidovski FS, Duus LS, Ottosen CI, Nielsen AB, Borchsenius JH, Espersen C, Köse G, Fussing FH, Pareek M, Køber L, Solomon SD, Jensen JUS, Martel CJ, Gessner BD, Schwarz C, Gonzalez E, Skovdal M, Moulton LH, Zhang P, Begier E, Biering-Sørensen T. Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial. JAMA. 2025 Oct 28;334(16):1431-1441. doi: 10.1001/jama.2025.15405. PMID: 40884493; PMCID: PMC12398766.
* Bronder S, Abu-Omar A, Lennartz S, Tschausowsky D, Radun R, Fliser D, Schmidt T, Wilkens H, Schmit D, Sester M. Cellular and humoral immunogenicity of respiratory syncytial virus vaccination in solid organ transplant recipients. Am J Transplant. 2026 Mar;26(3):499-511. doi: 10.1016/j.ajt.2025.09.023. Epub 2025 Oct 6. PMID: 41062073.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.